Address
PMB #117, 2801 Centerville Road
Wellesley Hills, MA 19808-1609
United States of America (the)
Phone
866 857 2596
Website
Sector
Healthcare
Industry
Biotechnology
Employees
29
First IPO Date
August 10, 2021
| Name | Title | Pay | Year Born |
| Aoife Brennan BCh MMSc | Chief Executive Officer, President & Director | 1.09M | 1976 |
| Susan Altschuller | CFO & Principal Accounting Officer | 570,812 | 1982 |
| Perrin Wilson | Chief Business Officer | 793,420 | 1979 |
| Edgar D. Charles | Chief Medical Officer | 0 | N/A |
| Ashley Jones | Senior Vice President of People & Workforce Strategy | 0 | N/A |
| Theresa Donegan | Vice President & Head of Quality | 0 | N/A |
| Janaki Subramanyam | Vice President & Head of Regulatory Affairs | 0 | N/A |
| Adam Villa | Senior Vice President of Technical Operations | 0 | N/A |
| Chandra Adams | VP, General Counsel & Secretary | 0 | N/A |
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.